BiologicalDrug
Peginterferon lambda-1a clinical trials
Also written BMS-914143 and Pegylated Interferon Lambda.
- studies test it
- 21
- open now
- 0
- in phase 3
- 8
- first study started
- 2007
How studies write it
Studies that test it under each name
Development codes
Other names
Studies by the year they started
21 studies that test it; most in 2013 (5)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 4 |
| 2013 | 5 |
| 2016 | 1 |
| 2020 | 4 |
| 2021 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 10
- Phase 3
- 8
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 6
Bristol-Myers Squibb (10) · University Health Network, Toronto (2) · ZymoGenetics (2) · Eiger BioPharmaceuticals (1) · EIT Pharma, Inc. (1) · Stanford University (1) · Nanogen Pharmaceutical Biotechnology Joint Stock Company (1) · Raymond Chung (1)
Often tested with
Tested in the same studies.
Daclatasvir (5) · Peginterferon alfa-2a (3) · Ribavirin (2) · Telaprevir (1) · Asunaprevir (1)
Studies
Open first, then newest update. How each study uses peginterferon lambda-1a is read from its arms, and is right about nine times in ten.
Testing it · 21
- A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus InfectionCompletedPhase 2EIT Pharma, Inc.NCT02765802Written as Peginterferon Lambda-1A
- Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta HepatitisWithdrawnPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT05953545Written as Peginterferon Lambda
- Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19CompletedPhase 2University Health Network, TorontoNCT04354259Written as Peginterferon Lambda-1A
- Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDVActive, not recruitingPhase 3Eiger BioPharmaceuticalsNCT05070364Written as Peginterferon Lambda-1a
- Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIVTerminatedPhase 3Bristol-Myers SquibbNCT01866930Written as Pegylated Interferon Lambda-1a
- Pegylated Interferon Lambda Treatment for COVID-19TerminatedPhase 2Raymond ChungNCT04343976Written as Pegylated interferon lambda
- TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19Status unknownPhase 3University Health Network, TorontoNCT04967430Written as Peginterferon Lambda-1A
- Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19CompletedPhase 2Stanford UniversityNCT04331899Written as Peginterferon Lambda-1a
- Interferon Lambda Therapy for COVID-19WithdrawnPhase 2Icahn School of Medicine at Mount SinaiNCT04388709Written as Peginterferon Lambda-1A
- Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With TelaprevirCompletedPhase 3Bristol-Myers SquibbNCT01598090Written as Peginterferon Lambda-1a
- The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C PatientsCompletedPhase 1Nanogen Pharmaceutical Biotechnology Joint Stock CompanyNCT02063607Written as Peginterferon lambda
- Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e AntigenCompletedPhase 2Bristol-Myers SquibbNCT01204762Written as PegIFN lambda
- Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) TherapyCompletedPhase 3Bristol-Myers SquibbNCT01718158Written as Peginterferon Lambda-1a
- Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3CompletedPhase 3Bristol-Myers SquibbNCT01616524Written as Pegylated interferon lambda (pegIFNλ)
- Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With RibavirinCompletedPhase 2Bristol-Myers SquibbNCT01309932Written as Pegylated Interferon Lambda (pegIFNλ)
- Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With RibavirinCompletedPhase 2Bristol-Myers SquibbNCT01795911Written as Pegylated Interferon Lambda
- Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis CCompletedPhase 3Bristol-Myers SquibbNCT01754974Written as Peginterferon Lambda-1a
- Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal DysfunctionCompletedPhase 1Bristol-Myers SquibbNCT01708889Written as BMS-914143 (Peginterferon Lambda-1a)
- Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis CWithdrawnPhase 3Bristol-Myers SquibbNCT01447394Written as Pegylated Interferon Lambda
- Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus InfectionStatus unknownPhase 2ZymoGeneticsNCT01001754Written as PEG-rIL-29
See all 21 studies that test peginterferon lambda-1a →
Given in every arm · 1 — peginterferon lambda-1a is usual care beside what is tested
Codes
What other systems call peginterferon lambda-1a · ClinicalTrials.gg INT000296
- MeSH (NLM) C000600496peginterferon lambda-1aOne source NLM
- UNII (FDA) 0T0250N43UPEGINTERFERON LAMBDA-1AConfirmed FDA, NLM
- NCI Thesaurus C166435Peginterferon Lambda-1AOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000600496 | peginterferon lambda-1a | One source NLM |
| UNII (FDA) | 0T0250N43U | PEGINTERFERON LAMBDA-1A | Confirmed FDA, NLM |
| NCI Thesaurus | C166435 | Peginterferon Lambda-1A | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.